donidalorsen

Sponsor Ionis Pharmaceuticals INC · listed as IONS

READOUT Phase 3 Confidence: medium Source: clinicaltrials

donidalorsen is a clinical-stage drug asset sponsored by Ionis Pharmaceuticals INC, listed as IONS. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2026 (month precision, medium confidence), tied to trial NCT05392114. The asset is in Phase 3 and currently active not recruiting, studied in Hereditary Angioedema. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2026-12-31

As disclosedDec 2026

Date precisionmonth

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT05392114

PhasePHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorIonis Pharmaceuticals, Inc.

Listed asIONS

Condition(s)Hereditary Angioedema

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More IONS catalysts